B-Cell Depletion in Focus: Pharmacodynamic and Biomarker Insights From MINT

As targeted therapies continue to evolve in generalized myasthenia gravis, pharmacodynamic data are becoming increasingly important for understanding how these treatments exert their effects at a biological level. In particular, evaluating the depth and durability of B-cell depletion offers insight into whether upstream immune modulation translates into sustained clinical benefit.

At the 2026 AAN Annual Meeting in Chicago, Richard Nowak, MD, MS, associate professor of neurology at Yale School of Medicine, discussed pharmacodynamic findings from the phase 3 MINT trial evaluating inebilizumab. These analyses provide important context around how CD19-targeted therapy impacts circulating B-cell populations and how these changes align with observed clinical outcomes over time.

In this episode, Nowak reviews reductions in circulating CD20-positive B cells as a surrogate marker for CD19-targeted depletion, emphasizing the rapid onset and sustained nature of B-cell suppression. He also addresses the current limitations of available biomarkers and the need for more precise tools to predict treatment response in patients with generalized myasthenia gravis.